An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Trial Profile

An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Risankizumab (Primary) ; Risankizumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors AbbVie; Boehringer Ingelheim
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 1 Aug 2022 to 8 Nov 2022.
    • 05 Oct 2017 Planned primary completion date changed from 1 Aug 2022 to 8 Nov 2022.
    • 04 May 2017 According to an AbbVie media release, data from this trial will be presented at Digestive Disease Week (DDW) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top